Hypertension, Vol 22, 139-146, Copyright © 1993 by American Heart Association
JN Wu and KH Berecek
Our purpose was to evaluate whether early treatment of spontaneously
hypertensive rats (SHR) with the angiotensin converting enzyme inhibitor
captopril could permanently alter the course of hypertension. Mating pairs
of SHR were treated with captopril, and their pups were maintained on
captopril until experimentation. Some captopril-treated rats were taken off
treatment at 2 months of age, and then some of these rats were mated at 3
months of age. The mean arterial pressures of conscious captopril-treated
rats, the rats removed from therapy, and the offspring of the rats removed
from therapy were significantly smaller than control rats at 4 and 9 months
of age. Central administration of angiotensin I or II induced significantly
smaller increases in blood pressure and drinking in captopril-treated rats
and the rats removed from therapy compared with control rats. The increase
in blood pressure in response to intravenous injection of angiotensin I or
II was similar among all groups, with the exception that captopril- treated
rats showed lesser pressor responses to angiotensin I. Early administration
of captopril, even after administration was stopped, prevented the
subsequent development of hypertension in SHR and altered the course of
development of hypertension in their progeny. This effect was associated
with decreased central responses to angiotensin I and II. Our data suggest
that captopril may permanently alter the development of hypertension in SHR
through an alteration in the central renin-angiotensin system.
ARTICLES
Prevention of genetic hypertension by early treatment of spontaneously hypertensive rats with the angiotensin converting enzyme inhibitor captopril
Department of Physiology and Biophysics, University of Alabama, Birmingham 35294.
This article has been cited by other articles:
 |
|
 |
|
  S. Kasparov and A. G. Teschemacher The use of viral gene transfer in studies of brainstem noradrenergic and serotonergic neurons Phil Trans R Soc B, September 12, 2009; 364(1529): 2565 - 2576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Skov, H. Eiskjaer, H. E. Hansen, J. K. Madsen, S. Kvist, and M. J. Mulvany Treatment of Young Subjects at High Familial Risk of Future Hypertension With an Angiotensin-Receptor Blocker Hypertension, July 1, 2007; 50(1): 89 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Schunkert A Dream Yet To Become True Hypertension, July 1, 2007; 50(1): 39 - 40. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gimenez, M. P. Garcia, M. Serna, B. Bonacasa, L. F. Carbonell, T. Quesada, and I. Hernandez 17{beta}-Oestradiol enhances the acute hypotensive effect of captopril in female ovariectomized spontaneously hypertensive rats Exp Physiol, July 1, 2006; 91(4): 715 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Julius, S. D. Nesbitt, B. M. Egan, M. A. Weber, E. L. Michelson, N. Kaciroti, H. R. Black, R. H. Grimm Jr., F. H. Messerli, S. Oparil, et al. Feasibility of Treating Prehypertension with an Angiotensin-Receptor Blocker N. Engl. J. Med., April 20, 2006; 354(16): 1685 - 1697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Racasan, B. Braam, H. A. Koomans, and J. A. Joles Programming blood pressure in adult SHR by shifting perinatal balance of NO and reactive oxygen species toward NO: the inverted Barker phenomenon Am J Physiol Renal Physiol, April 1, 2005; 288(4): F626 - F636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Nagai, L. Yao, H. Kobori, K. Miyata, Y. Ozawa, A. Miyatake, T. Yukimura, T. Shokoji, S. Kimura, H. Kiyomoto, et al. Temporary Angiotensin II Blockade at the Prediabetic Stage Attenuates the Development of Renal Injury in Type 2 Diabetic Rats J. Am. Soc. Nephrol., March 1, 2005; 16(3): 703 - 711. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. H. Schlenker, C. K. Kost Jr., and M. M. Likness Effects of long-term captopril and L-arginine treatment on ventilation and blood pressure in obese male SHHF rats J Appl Physiol, September 1, 2004; 97(3): 1032 - 1039. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Julius, S. Nesbitt, B. Egan, N. Kaciroti, M. A. Schork, M. Grozinski, E. Michelson, and for the TROPHY study group Trial of Preventing Hypertension: Design and 2-Year Progress Report Hypertension, August 1, 2004; 44(2): 146 - 151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Bertram, N. Blanc-Brunat, J. Sassard, and M. Lo Differential evolution of blood pressure and renal lesions after RAS blockade in Lyon hypertensive rats Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2002; 283(5): R1041 - R1045. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. NAKAYA, H. SASAMURA, M. HAYASHI, and T. SARUTA Temporary Treatment of Prepubescent Rats with Angiotensin Inhibitors Suppresses the Development of Hypertensive Nephrosclerosis J. Am. Soc. Nephrol., April 1, 2001; 12(4): 659 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. CARLEY, K. BERECEK, A. VIDENOVIC, and M. RADULOVACKI Sleep-disordered Respiration in Phenotypically Normotensive, Genetically Hypertensive Rats Am. J. Respir. Crit. Care Med., October 1, 2000; 162(4): 1474 - 1479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zicha and J. Kunes Ontogenetic Aspects of Hypertension Development: Analysis in the Rat Physiol Rev, October 1, 1999; 79(4): 1227 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chen, J. Su, K. Wu, W. Hu, D. G. Gardner, and D. Chen Early captopril treatment prevents hypertrophy-dependent gene expression in hearts of SHR Am J Physiol Regulatory Integrative Comp Physiol, June 1, 1998; 274(6): R1511 - R1517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Martens, P. Y. Reaves, D. Lu, M. J. Katovich, K. H. Berecek, S. P. Bishop, M. K. Raizada, and C. H. Gelband Prevention of renovascular and cardiac pathophysiological changes in hypertension by angiotensin II type 1 receptor antisense gene therapy PNAS, March 3, 1998; 95(5): 2664 - 2669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Lu, H. Yang, and M. K. Raizada Attenuation of ANG II actions by adenovirus delivery of AT1 receptor antisense in neurons and SMC Am J Physiol Heart Circ Physiol, February 1, 1998; 274(2): H719 - H727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Kubisch, S. Mathialagan, and E. P. Gomez-Sanchez Modulation of Blood Pressure in the Dahl SS/jr Rat by Embryo Transfer Hypertension, January 1, 1998; 31(1): 540 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Goto, M. Mukoyama, S.-i. Suga, T. Matsumoto, M. Nakagawa, R. Ishibashi, M. Kasahara, A. Sugawara, I. Tanaka, and K. Nakao Growth-Dependent Induction of Angiotensin II Type 2 Receptor in Rat Mesangial Cells Hypertension, September 1, 1997; 30(3): 358 - 362. [Abstract] [Full Text]
|
|
|
|
|
|
D. Lu, M. K. Raizada, S. Iyer, P. Reaves, H. Yang, and M. J. Katovich Losartan Versus Gene Therapy : Chronic Control of High Blood Pressure in Spontaneously Hypertensive Rats Hypertension, September 1, 1997; 30(3): 363 - 370. [Abstract] [Full Text]
|
|
|
|
|
|
B. S. Huang and F. H.H. Leenen Brain "Ouabain" and Angiotensin II in Salt-Sensitive Hypertension in Spontaneously Hypertensive Rats Hypertension, December 1, 1996; 28(6): 1005 - 1012. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Taddei, A. Virdis, P. Mattei, L. Ghiadoni, I. Sudano, and A. Salvetti Defective L-Arginine–Nitric Oxide Pathway in Offspring of Essential Hypertensive Patients Circulation, September 15, 1996; 94(6): 1298 - 1303. [Abstract] [Full Text]
|
|
|
|
|
|
K. Skov, J. Fenger-Gron, and M. J. Mulvany Effects of an Angiotensin-Converting Enzyme Inhibitor, a Calcium Antagonist, and an Endothelin Receptor Antagonist on Renal Afferent Arteriolar Structure Hypertension, September 1, 1996; 28(3): 464 - 471. [Abstract] [Full Text]
|
|
|
|
|
|
R. McCarty and J. H. Lee Preweanling Administration of Terazosin Decreases Blood Pressure of Hypertensive Rats in Adulthood Hypertension, May 1, 1996; 27(5): 1115 - 1120. [Abstract] [Full Text]
|
|
|
|
|
|
A. F. Dominiczak, A. M. Devlin, W. K. Lee, N. H. Anderson, D. F. Bohr, and J. L. Reid Vascular Smooth Muscle Polyploidy and Cardiac Hypertrophy in Genetic Hypertension Hypertension, March 1, 1996; 27(3): 752 - 759. [Abstract] [Full Text]
|
|
|
|
|
|
K. Kumagai, H. Suzuki, M. Ichikawa, M. Jimbo, M. Nishizawa, M. Ryuzaki, and T. Saruta Comparison of Early and Late Start of Antihypertensive Agents and Baroreceptor Reflexes Hypertension, February 1, 1996; 27(2): 209 - 218. [Abstract] [Full Text]
|
|
|
|
|
|
D. Rizzoni, M. Castellano, E. Porteri, G. Bettoni, M. L. Muiesan, A. Cinelli, and E. A. Rosei Effects of Low and High Doses of Fosinopril on the Structure and Function of Resistance Arteries Hypertension, July 1, 1995; 26(1): 118 - 123. [Abstract] [Full Text]
|
|
|
|
|
|
P. Madeddu, P. P. Parpaglia, M. P. Demontis, M. V. Varoni, M. C. Fattaccio, V. Anania, and N. Glorioso Early Blockade of Bradykinin B2-Receptors Alters the Adult Cardiovascular Phenotype in Rats Hypertension, March 1, 1995; 25(3): 453 - 459. [Abstract] [Full Text]
|
|
|
|
|
|
S. Oparil Cardiovascular Health at the Crossroads: Outlook for the 21st Century : Presented at the 67th Scientific Sessions of the American Heart Association November 4, 1994 Dallas, Texas Circulation, February 15, 1995; 91(4): 1304 - 1310. [Abstract] [Full Text]
|
|
|
|
|
|
J. B. O'Sullivan and S. B. Harrap Resetting Blood Pressure in Spontaneously Hypertensive Rats : The Role of Bradykinin Hypertension, February 1, 1995; 25(2): 162 - 165. [Abstract] [Full Text]
|
|